Week in Review: Celebrating Patient Health

07.03.14 | By

Before we leave to celebrate the holiday weekend, we wanted to talk about the latest happenings in the biopharmaceutical industry and the importance of celebrating patients.

Medicines in Development for Older Americans

07.03.14 | By

As overall life expectancy continues to grow, so does the number of older Americans, the majority of whom have at least one chronic disease. Chronic diseases not only impact our loved ones living with them, but our families as well and cost the health care system billions of dollars. Prospective medicines currently in the pipeline hold promise to improve health outcomes and provide cost savings.

Rx Response Benefits

07.01.14 | By

We all know that it only takes one storm to have severe impact, which is why we wanted to remind you that Rx Response stands ready to support any disaster that has wide-spread impact to pharmaceutical supply, and that all of our services are offered at no cost to government partners.

Week in Review: Ensuring Patients Have Access to Needed Treatments

06.27.14 | By

Biopharmaceutical research and development (R&D) is fueled by innovative minds with an eye toward the future. It has provided patients around the world with treatments to help them live healthier, more productive lives. This week, we focused on the ways in which innovation continues to help patients thrive and the unfortunate roadblocks that often hinder patient access to life-changing medicines.

ICYMI: Insurer: “Can drugs as expensive as these really be cost-effective? The answer is yes.”

06.25.14 | By

The focus in recent weeks on the cost of a new cure for Hepatitis C has largely ignored the long-term value it provides to patients and the health care system broadly, including helping to prevent expensive hospitalizations and costly medical procedures, such as liver transplants.

Restricting Access to Medicines At the Expense of Patients Warrants a Candid Conversation

06.23.14 | By

It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.

Investments in Innovation, Jobs, and Economic Development

06.20.14 | By

Innovation is the engine of economic growth and development.  Research and development (R&D) spending is what creates jobs and makes innovation a reality.  As the global economy continues to recover and regain its former strength, the pharmaceutical industry remains the world’s largest source of R&D spending.  According to a recent article in the

Week in Review: The Importance of Patient Perspectives

06.20.14 | By

“The biopharmaceutical industry’s top priority is to provide patients with access to innovative, life-saving medicines.”

Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.


Subscribe to RSS - Opinion